← Leaderboards
Judith A Kelleher-Andersson
Neuronascent, Inc.
$7,321,514
Attributed
$7,321,514
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2018–24$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,321,514 · 2
By mechanism
U01$4,543,556 · 1
R01$2,777,958 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposMaleNeuroprotective AgentsAgingContractorSafetySafety TestingSafety StudyNeuronsMeetingsRegenerative TherapyFemaleAgedImpaired CognitionFailureDoseAging PopulationRattusGrantOralPlasmaDrug KineticsDisease ModelFood
Grant awards (7)
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial$2,093,556
U01 · FY2024 · AG · contact PI
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial$350,000
U01 · FY2024 · AG · contact PI
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial$2,100,000
U01 · FY2023 · AG · contact PI
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$246,631
R01 · FY2021 · AG · contact PI
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$692,120
R01 · FY2019 · AG · contact PI
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$263,516
R01 · FY2019 · AG · contact PI
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$1,575,691
R01 · FY2018 · AG · contact PI